WILLIAM WARNES: Open Payments
NPI 1710937636 · LEAVENWORTH, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,040 in 54 payments from 12 companies in 2025. Trend: 2023 $558 · 2024 $181 · 2025 $1,040
Food & beverage: $1,040
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 6 | $224 |
| Otsuka America Pharmaceutical, Inc. | 9 | $156 |
| ABBVIE INC. | 13 | $137 |
| Neurocrine BioSciences, Inc. | 6 | $134 |
| Alkermes, Inc. | 7 | $126 |
| Janssen Pharmaceuticals, Inc | 3 | $63 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $51 |
| Neuronetics, Inc. | 1 | $48 |
| Teva Pharmaceuticals USA, Inc. | 2 | $31 |
| Axsome Therapeutics, Inc. | 2 | $31 |
Products named: COBENFY, VRAYLAR, INGREZZA, ARISTADA, ABILIFY ASIMTUFII, REXULTI, CAPLYTA, NEUROSTAR TMS THERAPY SYSTEM.
Industry payments across KS — which companies pay providers there.
